6G9B image
Deposition Date 2018-04-10
Release Date 2018-05-23
Last Version Date 2024-11-20
Entry Detail
PDB ID:
6G9B
Keywords:
Title:
Crystal structure of Ebolavirus glycoprotein in complex with imipramine
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.26 Å
R-Value Free:
0.22
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
H 3 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein,Envelope glycoprotein
Gene (Uniprot):GP
Mutations:T42A,T42A
Chain IDs:A
Chain Length:330
Number of Molecules:1
Biological Source:Zaire ebolavirus (strain Mayinga-76)
Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein
Gene (Uniprot):GP
Mutations:H613A
Chain IDs:B
Chain Length:168
Number of Molecules:1
Biological Source:Zaire ebolavirus (strain Mayinga-76)
Primary Citation
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
J. Med. Chem. 61 4938 4945 (2018)
PMID: 29741894 DOI: 10.1021/acs.jmedchem.8b00350

Abstact

A large number of Food and Drug Administration (FDA)-approved drugs have been found to inhibit the cell entry of Ebola virus (EBOV). However, since these drugs have various primary pharmacological targets, their mechanisms of action against EBOV remain largely unknown. We have previously shown that six FDA-approved drugs inhibit EBOV infection by interacting with and destabilizing the viral glycoprotein (GP). Here we show that antidepressants imipramine and clomipramine and antipsychotic drug thioridazine also directly interact with EBOV GP and determine the mode of interaction by crystallographic analysis of the complexes. The compounds bind within the same pocket as observed for other, chemically divergent complexes but with different binding modes. These details should be of value for the development of potent EBOV inhibitors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures